The document includes recommendations for the reporting and implementation of changes to container closure system components.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
On Nov. 7, 2023, FDA issued final guidance that includes recommendations for reporting post-approval changes of some common changes to container closure system (CCS) components consisting of glass vials and stoppers for approved sterile drug products and biologics. The recommendations apply to approved new drug applications (NDAs), biologics license applications (BLAs), and abbreviated new drug applications (ANDAs). Pathways available to application holders to obtain feedback from FDA are also presented. Risk-based tools for implementation of changes to CCSs consisting of glass vials and stoppers are provided. This guidance does not apply to CCS types other than glass vials and stoppers.
According to FDA, many COVID-19 products use glass vials and stoppers as their CCS, and the supply of these products may be constrained. Manufacturers, therefore, may need to update approved applications to reflect changes made to CCS components to fill demand. The agency will consider risk-based approaches to implementation of chemistry, manufacturing, and controls (CMC) changes to a CCS so that supply of products is not impeded.
The guidance details common changes related to glass vials and stoppers and provides information on tools that can facilitate changes to CCS components. “FDA may expedite the assessment of a supplement or determine that a different reporting category is appropriate, taking into account public health priorities and the applicant’s rationale and associated risk assessment and mitigation strategy for the proposed change. Should a different reporting category be determined to be appropriate, FDA will notify the applicant and convey its rationale for the determination,” the agency states in the document.
The policy remains in effect until Aug. 7, 2024 unless a revised final guidance is published before then. More information can be found in the Federal Register at https://www.federalregister.gov/documents/2023/03/13/2023- 05094/guidance-documents-related-to-coronavirus-disease-2019-covid-19
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.